Generate Key Takeaways What are the most common COVID-19 symptoms doctors are seeing in025? Read on to find out what to look ...

Researchers say people using a common allergy nasal spray, azelastine, were 69% less likely to contract COVID-19.

Symptomatic or viral rebound is estimated to occur in 0.8% to 32% of Paxlovid recipients and 1.1% to 31% of those who receive ...

Researchers discuss the effects of azelastine nasal spray on the rate of SARS-CoV-2 infection as compared to placebo.

Risk for developing long COVID doubled in kids who got infected with SARS-CoV-2 a second time. Reinfection's greater risk also held up in a range of potential long COVID-related conditions and ...

The flu causes millions of illnesses, hundreds of thousands of hospitalizations and tens of thousands of deaths each year in ...

The Times Network India Health Summit 2025 highlighted dengue’s growing threat. Experts called for early diagnosis, ...

Meinel and his colleagues arrived at a crafty cost-cutter: using one of the body’s own molecular detection systems, the ...

The AVTOZMA ® (tocilizumab-anoh) intravenous (IV) formulation was approved in January 2025 by the FDA to treat the same ...

Dengue has been a persistent issue in India and people often have their set of questions regarding the precautions, medicine, ...

Instead of increasing as predicted by pathogen stress theory, the difference between in-group and out-group trust fell in the ...

Covid infections are rising as colder weather arrives, with data from the UK Health Security Agency showing a 60% rise in the ...